Roots Analysis has done a detailed study on Global
Autoinjectors Market (3rd Edition), 2020-2030.”, covering key
aspects of the industry’s evolution and identifying potential future growth
opportunities.
To order this 600+ page report, which features 360+ figures
and 350+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html
Key Market Insights
§ Currently, several companies claim to be engaged in the development
/ manufacturing of various types of autoinjectors, most of which are disposable
systems that use prefilled syringes as primary drug containers
§ About 90
autoinjector-based combination products have been approved for the treatment of
a variety of clinical conditions; the subcutaneous route being the preferred
mode of drug delivery via such devices
§ In order to gain a competitive edge in the
market, many autoinjector manufacturers are focusing on the integration of
advanced features into their respective products and affiliated offerings
§ Over time, more than 4,600 patents have been
filed / granted related to autoinjectors and affiliated products; most of the
new intellectual property is related to additional features, such as safety
locks and device connectivity
§ Eminent scientists from
renowned organizations and academic institutions across the world have made
valuable contributions to this field, in terms of leading clinical research
efforts and developing novel technologies
§ Several autoinjector developers
have established strong brand positions in different geographies; the focus, in
the near term, is likely to be on further enhancing device features for better
disease management and improved patient compliance
§ An evaluation of 200+
marketed and pipeline products revealed that a variety of drugs / product
candidates are likely to be considered for administration via autoinjectors in
the near future
§ Case Study: Owing to the complexities
associated with the manufacturing and assembly of autoinjector drug delivery
systems, industry players are known to frequently engage the services of
contract service providers
§ Currently, disposable
autoinjector products for small molecule drugs dominate the market; however, in
the foreseen future, the demand for reusable devices is anticipated to witness
significant growth
§ Given the recent
approvals and presence of multiple drug candidates in later stages of
development, the market opportunity is likely to be distributed across
different therapeutic areas, routes of administration and geographies
For more information, please visit https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Drug Delivery Systems
3.3. Drawbacks of Conventional Parenteral
Delivery Systems
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Government Legislation for the
Prevention of Needlestick Injuries
3.5. Emerging Trend of Self-Administration
3.5.1. Rising Burden of Chronic Diseases
3.5.2. Healthcare Cost Savings
3.5.3. Need for Immediate Treatment in
Emergency Situations
3.5.4. Growth of Injectable Biologics Market
3.5.5. Addressing Key User Safety Requirements
3.6. Types of Self- Administration Devices
3.6.1. Prefilled Syringes
3.6.2. Pen-Injectors
3.6.3. Needle-Free Injectors
3.6.4. Autoinjectors
3.6.5. Large Volume Wearable Injectors
3.7. Overview of Autoinjectors
3.7.1. Components of Autoinjectors
3.7.2. Classification of Autoinjectors
3.7.2.1. On the Basis of Mechanism of Action
3.7.2.2. On the Basis of Usability
3.7.2.3. On the Basis of Type of Dose
3.7.3. Manufacturing / Packaging of
Autoinjectors
3.7.4. Benefits of Autoinjectors
3.8. Regulatory Considerations
3.8.1. Medical Devices
3.8.2. Drug Device Combination Products
3.9. Future Perspectives
4. PRIMARY DRUG CONTAINERS
4.1. Chapter Overview
4.2. Types of Packaging
4.3. Introduction to Primary Drug
Containers
4.3.1. Role of Primary Drug Containers
4.3.2. Types of Primary Drug Containers
4.3.2.1. Cartridges
4.3.2.1.1. Components of Cartridges
4.3.2.1.2. Types of Cartridges
4.3.2.1.2.1. Single Chamber Cartridge
4.3.2.1.2.2. Dual Chamber Cartridge
4.3.2.1.3. Cartridges Available in the Market
4.3.2.2. Syringes
4.3.2.2.1. Components
4.3.2.2.2. Types of Syringes
4.3.2.2.2.1. Based on Number of Chambers
4.3.2.2.2.2. Based on Type of Needle
4.3.2.2.3. Prefilled Syringe Systems Available in the
Market
4.3.2.2.3.1. Glass Prefilled Syringes
4.3.2.2.3.2. Plastic Prefilled Syringes
4.3.2.3. Vials
4.3.2.3.1. Components
4.3.2.3.2. Vials Available in the Market
4.4. Comparison of Fabrication Materials
5. AUTOINJECTORS: CURRENT MARKET
LANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: List of Devices
5.2.1. Analysis by Usability
5.2.2. Analysis by Type of Primary Container
5.3. Autoinjectors: List of Additional
Parameters of Devices
5.3.1. Analysis by Volume of Container
5.3.2. Analysis by Type of Dose
5.3.3. Analysis by Route of Administration
5.3.4. Analysis by Actuation Mechanism
5.3.5. Analysis by Type of Feedback Mechanism
5.4. Autoinjectors: List of Developers
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Geographical Location of
Headquarters
6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis
6.4.1. Disposable Autoinjectors
6.4.2. Reusable Autoinjectors
7. BRAND POSITIONING ANALYSIS OF KEY
INDUSTRY PLAYERS
7.1 Chapter Overview
7.2. Scope and Methodology
7.3. Brand Positioning Matrix: Antares
Pharma
7.4. Brand Positioning Matrix: BD
7.5. Brand Positioning Matrix: DALI
Medical Devices
7.6. Brand Positioning Matrix: Elcam Drug
Delivery Devices
7.7. Brand Positioning Matrix: Oval
Medical Technologies
7.8 Brand Positioning Matrix: Owen
Mumford
7.9. Brand Positioning Matrix: SHL Medical
7.10 Brand Positioning Matrix: Union Medico
7.11. Brand Positioning Matrix: Ypsomed
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Autoinjectors: Patent Analysis
8.3.1. Analysis by Application Year
8.3.2. Analysis by Issuing Authority
8.3.3. Analysis by CPC Symbols
8.4. Emerging Areas
8.5. Leading Players Based on Number of
Patents
8.6. Autoinjectors: Patent Benchmarking
Analysis
8.6.1. Analysis by Patent Characteristics
8.6.2. Analysis by Geography
8.7. Autoinjectors: Patent Valuation
Analysis
9. THERAPEUTIC PRODUCTS AVAILABLE IN
AUTOINJECTORS
9.1. Chapter Overview
9.2. Autoinjector Combination Products:
List of Approved Drugs
9.2.1. Analysis by Initial Year of Approval
9.2.2. Analysis by Usability
9.2.3. Analysis by Route of Administration
9.2.4. Analysis by Primary Drug Container
9.3. Approved Autoinjector Combination
Products: List of Additional Parameters
9.3.1. Analysis by Type of Molecule
9.3.2. Analysis by Dose Strength
9.3.3. Analysis by Therapeutic Indication
9.3.4. Analysis by Other Packaging Formats of
Marketed Drugs
9.4. Autoinjector Combination Products:
List of Pipeline Drugs
9.4.1. Analysis by Phase of Development
9.5. Pipeline Autoinjector Combination
Products: List of Additional Parameters
9.5.1. Analysis by Route of Administration
9.5.2. Analysis by Type of Molecule
9.5.3. Analysis by Therapeutic Indication
9.5.4. Grid Analysis: Distribution by
Therapeutic Indication, Phase of Development and Route of Administration
9.6. Autoinjector Combination Products:
List of Developers
9.6.1. Analysis by Year of Establishment
9.6.2. Analysis by Company Size
9.6.3. Analysis by Location of Headquarters
10. CASE STUDY: AUTOINJECTOR-BASED
COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS
10.1. Chapter Overview
10.2. Marketed / Pipeline Drugs Being
Evaluated with Autoinjectors
10.3. Case Study I: Anaphylaxis
10.3.1. Overview and Epidemiology
10.3.2. Adrenaline: Mechanism of Action
10.3.3. History of Development
10.3.4. Marketed Adrenaline / Epinephrine
Autoinjectors
10.3.4.1. Adrenaclick
10.3.4.2. Allerject / Auvi-Q (Formerly called e-cue)
10.3.4.3. Anapen
10.3.4.4. Emerade
10.3.4.5. EpiPen / EpiPen Jr
10.3.4.6. Jext
10.3.4.7. EpiPen / EpiPen Jr
10.3.5. Adrenaline / Epinephrine Autoinjectors
Under Development
10.3.5.1. EpiQ
10.3.5.2. ANDIPen
10.3.5.3. MiniEpi
10.3.5.4. Zeneo Adrenaline
10.3.6. Other Dosage Forms
10.3.7. Historical Sales of Approved Drugs /
Autoinjectors
10.4. Case Study II: Multiple Sclerosis
10.4.1. Overview and Epidemiology
10.4.2. Interferon β-1a
10.4.3. Interferon β-1b
10.4.4. Interferons: Mechanism of Action
10.4.5. History of Development
10.4.6. Interferon β-1a Autoinjectors
10.4.6.1. Avonex Pen
10.4.6.2. PLEGRIDY Pen
10.4.6.3. Rebif Rebidose
10.4.6.4. RebiSmart
10.4.6.5. Rebiject II
10.4.6.6. ReciGen Physioject
10.4.7. Interferon β-1b Autoinjectors
10.4.7.1. BETACONNECT
10.4.7.2. BETAJECT Comfort / Betacomfort
10.4.7.3. Betaject Lite
10.4.7.4. ExtaviJect 30G / ExtaviPro 30G
10.4.8. Other Marketed Autoinjectors
10.4.8.1. Cinnomer40 Physioject
10.4.8.2. CSYNC Autoinjector
10.4.8.3. WhisperJECT
10.4.8.4. Remurel Autoxon
10.4.9. Other Dosage Forms
10.4.10. Historical Sales of Approved Drugs /
Autoinjectors
10.4.10.1. Interferon β-1a
10.4.10.2. Interferon β-1b
10.5. Case Study III: Migraine
10.5.1. Overview and Epidemiology
10.5.2. Sumatriptan Succinate: Mechanism of
Action
10.5.3. History of Development
10.5.4. Marketed Autoinjectors
10.5.4.1. ALSUMA
10.5.4.2. IMITREX STATdose Pen
10.5.4.3. Zembrace SymTouch
10.5.4.4. Aimovig SureClick Autoinjector
10.5.4.5. Emgality Prefilled Pen
10.5.5. Other Dosage Forms
10.5.6. Historical Sales of Approved Drugs /
Autoinjectors
10.6. Case Study IV: Rheumatoid Arthritis
10.6.1. Overview and Epidemiology
10.6.2. History of Development
10.6.3. Marketed Autoinjectors for Rheumatoid
Arthritis
10.6.3.1. Actemra
10.6.3.2. CIMZIA AutoClicks Prefilled Pen
10.6.3.3. Enbrel SureClick
10.6.3.4. Hulio Prefilled Pen
10.6.3.5. HUMIRA Pen
10.6.3.6. ORENCIA ClickJect
10.6.3.7. OTREXUP
10.6.3.8. Rasuvo Autoinjector
10.6.3.9. SIMPONI SmartJect Autoinjector
10.6.3.10. KEVZARA Prefilled Pen
10.6.3.11. IMRALDI Prefilled Pen
10.6.4. Historical Sales of Approved Drugs /
Autoinjectors
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
